KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Common Equity (2017 - 2025)

Historic Common Equity for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to -$110.0 million.

  • Amneal Pharmaceuticals' Common Equity fell 1751.47% to -$110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.0 million, marking a year-over-year decrease of 1751.47%. This contributed to the annual value of -$109.5 million for FY2024, which is 64725.9% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Common Equity stood at -$110.0 million, which was down 1751.47% from -$112.5 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Common Equity high stood at $407.4 million for Q1 2022, and its period low was -$132.0 million during Q1 2025.
  • Moreover, its 5-year median value for Common Equity was $150.8 million (2023), whereas its average is $118.3 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Common Equity surged by 1109.85% in 2022 and then plummeted by 64725.9% in 2024.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Common Equity stood at $367.0 million in 2021, then tumbled by 49.87% to $184.0 million in 2022, then plummeted by 89.12% to $20.0 million in 2023, then plummeted by 647.26% to -$109.5 million in 2024, then decreased by 0.4% to -$110.0 million in 2025.
  • Its Common Equity stands at -$110.0 million for Q3 2025, versus -$112.5 million for Q2 2025 and -$132.0 million for Q1 2025.